Samsung Biologics to Invest in Pharmaceutical “Super Plant”

Goodwin
Contact

GoodwinOn Tuesday, August 11, Samsung Biologics announced it will invest $2 billion to build a new pharmaceutical “super plant” in Incheon, South Korea. According to the press release, the new facility is part of Samsung’s long term strategy to maximize its operational efficiency and scale up its development and manufacturing capabilities in response to growing manufacturing demands.

The new plant, Samsung’s fourth, will be as large as its existing three plants combined and will hold 256 kiloliters total capacity upon completion. Samsung Biologics reports that the new plant will invest in offsetting its’ environmental impact through streamlined application, smart disposal of high-concentration wastewater, and an improvement in nitric acid emissions.  Plant 4 is scheduled to commence manufacturing in the second half of 2022.

The expansion plans come as demand for outsourced manufacturing of therapeutics, including COVID-19 treatment candidates, has increased, with Samsung Biologics having signed deals worth about 2.5 times last year’s total revenue in the first half of 2020 alone.

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Goodwin | Attorney Advertising

Written by:

Goodwin
Contact
more
less

Goodwin on:

Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
- hide
- hide

This website uses cookies to improve user experience, track anonymous site usage, store authorization tokens and permit sharing on social media networks. By continuing to browse this website you accept the use of cookies. Click here to read more about how we use cookies.